Search
forLearn
5 / 801 resultslearn Capixyl
learn enoxolone
learn Neoxyl
learn Naltrexone
Research
5 / 1000+ resultsresearch Probable drug‐triggered pemphigus foliaceus in a dog following administration of afoxolaner (NexGard)
A dog developed a skin condition called pemphigus foliaceus after taking NexGard, but got better with treatment.
research Successful management of demodicosis (Demodex canis) in a husky with Nexgard
Nexgard successfully treated a husky's demodicosis.
research A case of demodicosis in a dog successfully managed with Nexgard®
Nexgard® effectively treated a dog's skin condition, demodicosis.
research Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig
Afoxolaner effectively treats mange in guinea pigs with one dose.
research Canine alopecia X-Like disorder
The dog likely has a condition similar to Canine alopecia X.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.